posted on 2012-07-24, 00:00authored byZhonghan Yang, Viktoriya Grinchuk, Siu Po Ip, Chun-Tao Che, Harry H. S. Fong, Lixing Lao, Justin C. Wu, Joseph J. Sung, Brian Berman, Terez Shea-Donohue, Aiping Zhao
Irritable bowel syndrome (IBS) is a unctional bowel disorder and the etiology is not well understood. Currently there is no
cure for IBS and no existing medication induces symptom relief in all patients. IBS-20 is a 20-herb Chinese medicinal formula
that offers beneficial effects in patients with IBS; however, the underlying mechanisms are largely unknown. This study showed
that IBS-20 potently inhibited LPS- or IFNΓ-stimulated expression of pro-inflammatory cytokines, as well as classically activated
macrophage marker nitric oxide synthase 2. Similarly, IBS-20 or the component herb Coptis chinensis decreased LPS-stimulated
pro-inflammatory cytokine secretion from JAWS II dendritic cells. IBS-20 or the component herbs also blocked or attenuated the IFNΓ-induced drop in transepithelial electric resistance, an index of permeability, in fully differentiated Caco-2 monolayer.
Finally, the up-regulation of key inflammatory cytokines in inflamed colon from TNBS-treated mice was suppressed significantly by orally administrated IBS-20, including IFNΓ and IL-12p40. These data indicate that the anti-inflammatory activities of IBS-20 may contribute to the beneficial effects of the herbal extract in patients with IBS, providing a potential mechanism of action for IBS-20. In addition, IBS-20may be a potential therapeutic agent against other Th1-dominant gut pathologies such as inflammatory bowel disease.
Funding
This work was supported by the Pilot Project from NICCM 1U19 AT003266-04.